Morgan Stanley’s Xeris Biopharma Holdings XERS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$17M Sell
3,642,584
-645,697
-15% -$3.02M ﹤0.01% 2971
2025
Q1
$23.5M Buy
4,288,281
+1,410,765
+49% +$7.75M ﹤0.01% 2528
2024
Q4
$9.75M Buy
2,877,516
+523,208
+22% +$1.77M ﹤0.01% 3438
2024
Q3
$6.71M Buy
2,354,308
+744,384
+46% +$2.12M ﹤0.01% 3728
2024
Q2
$3.62M Buy
1,609,924
+318,966
+25% +$718K ﹤0.01% 4145
2024
Q1
$2.85M Sell
1,290,958
-1,151,758
-47% -$2.55M ﹤0.01% 4351
2023
Q4
$5.74M Buy
2,442,716
+1,804,484
+283% +$4.24M ﹤0.01% 4288
2023
Q3
$1.19M Buy
638,232
+306,845
+93% +$571K ﹤0.01% 4697
2023
Q2
$868K Buy
331,387
+177,047
+115% +$464K ﹤0.01% 4917
2023
Q1
$252K Buy
154,340
+35,582
+30% +$58K ﹤0.01% 5601
2022
Q4
$158K Buy
118,758
+1,188
+1% +$1.58K ﹤0.01% 5766
2022
Q3
$185K Sell
117,570
-9,641
-8% -$15.2K ﹤0.01% 5760
2022
Q2
$195K Sell
127,211
-13,318
-9% -$20.4K ﹤0.01% 5917
2022
Q1
$360K Sell
140,529
-1,210,258
-90% -$3.1M ﹤0.01% 5585
2021
Q4
$3.96M Buy
1,350,787
+1,104,830
+449% +$3.24M ﹤0.01% 3961
2021
Q3
$603K Buy
245,957
+97,992
+66% +$240K ﹤0.01% 5371
2021
Q2
$602K Sell
147,965
-168,249
-53% -$685K ﹤0.01% 5409
2021
Q1
$1.43M Buy
316,214
+275,064
+668% +$1.24M ﹤0.01% 4504
2020
Q4
$202K Buy
41,150
+30,292
+279% +$149K ﹤0.01% 5588
2020
Q3
$64K Sell
10,858
-32,045
-75% -$189K ﹤0.01% 5625
2020
Q2
$114K Buy
42,903
+39,748
+1,260% +$106K ﹤0.01% 5342
2020
Q1
$6K Sell
3,155
-41,635
-93% -$79.2K ﹤0.01% 6160
2019
Q4
$315K Buy
44,790
+36,905
+468% +$260K ﹤0.01% 5184
2019
Q3
$78K Buy
7,885
+7,362
+1,408% +$72.8K ﹤0.01% 5532
2019
Q2
$6K Sell
523
-52,593
-99% -$603K ﹤0.01% 6280
2019
Q1
$534K Buy
53,116
+42,406
+396% +$426K ﹤0.01% 4506
2018
Q4
$182K Sell
10,710
-2,676
-20% -$45.5K ﹤0.01% 5317
2018
Q3
$235K Buy
13,386
+12,663
+1,751% +$222K ﹤0.01% 5377
2018
Q2
$13K Buy
+723
New +$13K ﹤0.01% 6245